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Abstract
In attaining UNAIDS targets of 90-90-90 to achieve epidemic control, understanding who
the current utilizers of HIV treatment services are will inform efforts aimed at reaching those
not being reached. A retrospective chart review of CAPRISA AIDS Treatment Program
(CAT) patients between 2004 and 2013 was undertaken. Of the 4043 HIV-infected patients
initiated on ART, 2586 (64.0%) were women. At ART initiation, men, compared to women,
had significantly lower median CD4+ cell counts (113 vs 131 cells/mm3, p <0.001), lower
median body mass index (BMI) (21.0 vs 24.2 kg/m2, p<0.001), higher mean log viral load
(5.0 vs 4.9 copies/ml, p<0.001) and were significantly older (median age: 35 vs. 32 years,
p<0.001). Men had higher mortality rates compared to women, 6.7 per 100 person-years
(p-y), (95% CI: 5.8–7.8) vs. 4.4 per 100 p-y, (95% CI: 3.8–5.0); mortality rate ratio: 1.54,
(95% CI: 1.27–1.87), p <0.001. Age-standardised mortality rate was 7.9 per 100 p-y (95%
CI: 4.1–11.7) for men and 5.7 per 100 p-y (95% CI: 2.7 to 8.6) for women (standardised mor-
tality ratio: 1.38 (1.15 to 1.70)). Mean CD4+ cell count increases post-ART initiation were
lower in men at all follow-up time points. Men presented later in the course of their HIV dis-
ease for ART initiation with more advanced disease and experienced a higher mortality rate
compared to women.
Introduction
In South Africa, an estimated 6.2 million people are currently living with HIV infection [1].
South Africa has been successful in implementing the largest anti-retroviral programme in the
world with more than 3 million HIV infected people currently on treatment [2]. Despite this,
high HIV incidence rates continue to occur, and HIV related morbidity and mortality domi-
nates as the main cause of hospitalization and premature death for the last 2 decades [3].
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In order to achieve the UNAIDS 90-90-90 goals for epidemic control and enhance individ-
ual and population level impact of public access anti-retroviral therapy (ART), detailed under-
standing of gaps in access to treatment services and factors that contribute to poor HIV
treatment outcomes including ongoing mortality, is imperative. Data from other countries are
inconsistent and contradictory, with some studies demonstrating gender imbalances in access
to HIV treatment services and in clinical outcomes among patients on ART [4,5], and others
demonstrating poorer clinical outcomes in women [6–8] or no gender difference in immuno-
logical response or mortality [9].
Notwithstanding the higher burden in women and 5–7 year earlier acquisition of HIV
infection in adolescent girls and young women between the ages of 15–24 years [10], men are
known to be poor utilizers of health care services [11] and characteristically present at a late
stage of disease [12]. Women, are the predominant users of public sector ART [13], with
reports from South Africa indicating that up to 60% of eligible women received ART com-
pared to 41% of eligible men by mid-2011 [14]. This reflects the reality that infected women
are linked to care through routinely offered HIV testing when utilizing antenatal and other
sexual reproductive health services; an option that is not available for men.
A South African study assessing the sustainability of task shifting in a rural primary care
clinic demonstrated that 68.8% of those accessing ART services between 2004 and 2010
(p< 0.05) were women [15], and those men that access ART are less likely to be retained in
care [16].
In a country with the largest ART rollout program, it is important to understand who the
current utilizers of HIV treatment services are, as this will help inform efforts aimed at reach-
ing those currently not being reached. This study sought to investigate whether there were gen-
der and age differences in those accessing HIV care services and clinical outcomes in those




We undertook a retrospective chart review of ambulant HIV infected, ART naïve adult
patients enrolled into the PEPFAR-funded CAPRISA AIDS Treatment Programme (CAT)
between June 2004 and August 2013. Patients were enrolled from two different catchment
populations in KwaZulu-Natal; a TB clinic in the urban eThekwini district and a rural primary
health care clinic in Vulindlela, rural KwaZulu-Natal. ART eligibility criteria, and definitions
of immunologic and virological response to ART, defined as<400 copies/ml was as per cur-
rent South African Government HIV/AIDS treatment guidelines [17]. Following ART initia-
tion, patients presented for clinical review and adherence assessment weekly for the first two
weeks, then monthly for the first 6 months, and every 3 months thereafter unless clinically
indicated.
Routine demographic and clinical data were recorded at baseline and at follow-up visits.
Laboratory safety assessments and CD4+ cell counts and viral loads were conducted at baseline
and every 6 months or as clinically indicated. Patients were regarded as lost to follow-up if
they missed 3 consecutive scheduled visits and if all attempts to track them telephonically and
physically had failed. No lost to follow-up patients re-engaged in care. Patients provided writ-
ten informed consent for participation in the CAT programme and for the use of their medical
records. Approval for data collection and analysis was obtained from the University of Kwa-
Zulu-Natal, Biomedical Research Ethics Committee (Ref: E248/05).
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Data analysis
We used unpaired t-test, and Wilcoxon rank sum test for continuous data and Fisher’s exact
test for categorical data to compare demographics and clinical characteristics between men
and women. Data was censored at 72 months of follow-up. Kaplan-Meier was used to con-
struct survival curves and compare them using the log-rank test. Poisson approximations and
F-tests were used to construct 95% confidence intervals (CI) for mortality rate, TB incidence
rate and rate ratios, respectively. We calculated age-standardised mortality rates using 5-year
age band. The province of KwaZulu-Natal was used as a standard population. Predictors of
mortality were assessed through both univariate and multivariate proportional hazards regres-
sion. Proportionality was assessed by fitting time dependent covariates in a model created by
interacting baseline variables with survival time.
The association between gender and CD4+ cell count was determined through linear
mixed models. All models were adjusted for baseline covariates such as clinic site, age, tubercu-
losis status at baseline, past history of TB, WHO stage, CD4+ cell count and viral load. We con-
ducted sensitivity analysis evaluating the impact of ART programme maturity on the effect of
gender on mortality during ART initiation periods of 2004–2008 and 2009–2013.
We calculated attributable risk in order to assess the relative contribution and impact of
specific covariates on mortality. The effect of loss to follow-up on mortality was determined
through sensitivity analysis. P values less than 0.05 were considered statistically significant. All
analyses were conducted using SAS, version 9.4 (SAS Institute INC., Cary) and R version 3.2.2.
Role of the funding source. The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the report. The corresponding
author had full access to all the data in the study and had final responsibility for the decision to
submit for publication.
Results
Patient baseline clinical characteristics
A total of 4043 ambulant HIV infected patients, 1457 (36%) men and 2586 women (64%), 14
years and older, were initiated on ART between June 2004 and August 2013. Baseline clinical
characteristics are presented in Table 1. Women comprised 59.4% and 40.6%, (p<0.001) of
the study cohort at the urban and rural sites, respectively. Men were older, (median age of 35
vs 32 years), p<0.001, presented more often with WHO stage 4 disease (14.3% vs 9.7%),
p<0.001 and were more likely to have had a past history of tuberculosis (TB) (34.4% vs
26.3%), p<0.001, (Table 1). At ART initiation, men had lower median CD4+ cell counts (113
vs131 cells/mm3), p<0.001, a lower median body mass index (BMI) (21.0 vs 24.2 kg/m2),
p<0.001 and higher mean log viral loads (5.0 vs 4.9 copies/ml), p<0.001 (Table 1). The overall
retention rate at 72 months was 91.8%, with 89.9% of men compared to 91.8% of women
(p = 007) retained in care. Men and women were loss to follow-up at a median (IQR) of 9.7
(2.7–23.7) and 12.6 (4.4–27.2) months respectively (p = 0.118). Rates of viral suppression,
(89.5% vs 96%, p = 0.094) and proportion diagnosed with TB after ART initiation, (3.8% vs
4.2%, p = 0.620), did not differ significantly between men and women. In contrast, ART regi-
men change; 71% vs 9.5% p = 0.012 was significantly different between men and women
(Table 1).
Mortality
Deaths occurred among 173 men and 239 women, over 8033.71 person-years of follow-up,
(median of 16.3 months [interquartile range (IQR), 8.1 to 35]), (Fig 1). Overall mortality rates
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were 5.1 per 100 person-years (p-y) (95% CI: 4.6–5.6) and 6.7 per 100 p-y (95% CI: 5.8–7.8) in
men and 4.4 per 100 p-y (95% CI: 3.8–5.0) among women (mortality rate ratio: 1.54 (95% CI:
1.29–1.91, p< 0.001), (Fig 1). Age-standardised mortality rate was 7.9 per 100 p-y (95% CI:
4.1–11.7) for men and 5.7 per 100 p-y (95% CI: 2.7 to 8.6) for women (standardised mortality
ratio: 1.38 (1.15 to 1.70). Mortality rates observed for men and women were significantly dif-
ferent at all follow-up time points up to 72 months; men had higher mortality rates throughout
follow-up; peaking in the first 6 months post ART initiation at 15.2 (95% CI: 12.3–18.4) and
10.2 (95% CI: 8.5–12.2), between men and women respectively, p = 0.004 (Fig 1).
Mortality rates were highest in young men between the ages of 20 and 24 years at 11.8 per
100 p-y, (95% CI: 5.7–21.8) vs 3.9 per 100 p-y (95% CI: 2.4–5.9) in women of the same age,
mortality rate ratio: 3.06 (95% CI: 1.45–6.46), p = 0.003 (Table 2). Among those 25 years,
mortality rates among men were significantly different compared to women: 6.6 per 100 p-y
(95% CI 5.6–7.7) vs 4.4 per 100 p-y (95% CI 3.9–5.1), mortality rate ratio: 1.49 (95% CI: 1.21–
1.83), p<0.001 (Table 2). The mortality rate between men and women stratified by baseline
CD4+ cell count was 10.7 (95% CI 8.3–13.6) and 8.2 (95% CI 6.5–10.1) for patients with base-
line CD4+ cell counts <50 cells/mm3, p = 0.098; 5.4 (95% CI 4.3–6.7) and 3.8 (95% CI 3.2–4.6)
for baseline CD4+ cell counts of 50–200 cells/mm3, p = 0.012 and 5.2 (95% CI 2.8–8.9) and 2.1
(95% CI 1.2–3.3). Mortality rate ratio stratified by baseline CD4+ cell count comparing men






Characteristics at ART initiation
Overall age (years), median(IQR) 35 (30–41) 32 (28–38) <0.001
Age group: n (%)
<24 45 (3.1) 232 (9.0) <0.001
24–34 655 (45.0) 1350 (52.3)
35+ 757 (52.0) 1001 (38.8)
BMI(kg/m2), median(IQR) 21 (19.0–3.2) 24.2 (21.1–28.1) <0.001
CD4+ cell count (cells/mm3), median(IQR)a 113 (47–177) 131 (68–189) <0.001
CD4+ cell count, cells/mm3: n (%)
<50 344 (25.9) 423 (18.3) <0.001
50–200 783 (58.9) 1428 (61.6)
>200 203 (153) 466 (20.1)
Log VL, mean(SD)b 50 (0.9) 4.9 (0.9) <0.001
Rural site, n (%) 692 (47.5) 1536 (59.4) <0.001
Urban site, n (%) 765 (52.5) 1050 (40.6)
WHO stage 1–3, n (%)c 1244 (85.7) 2315 (90.3) <0.001
WHO stage 4, n (%)c 208 (14.3) 250 (9.7)
Previous history of TB, n (%)d 483 (34.4) 661 (26.3) <0.001
Prevalence of TB, n (%) 467 (32.1) 505 (19.5) <0.001
Follow-up
Number initiated on second line ART, n (%) 104 (7.1) 245 (9.5) 0.012
Lost to follow-up 161 (11.1) 239 (9.2) 0.070
a396 patents had missing baseline CD4+ count,
b496 missing VL,
c26 missing WHO stage,
d121 missing previous history TB
https://doi.org/10.1371/journal.pone.0184124.t001
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and women was 1.31 (95% CI 0.95–1.8) for baseline CD4+ cell counts < 50 cells/mm3,
p = 0.098; 1.42 (95% CI 1.08–1.87) for baseline CD4+ cell counts of 50–200 cells/mm3,
p = 0.012 and 2.1 (95% CI 1.22–5.26) for baseline CD4+ cell counts of> 200 cells/mm3
(Table 2).
Treatment response
Women demonstrated a better immunological response during ART follow-up showing con-
sistently higher mean CD4+ cell counts at each clinical assessment (Fig 2). Mean CD4+ cell
count increases post-ART initiation were lower in men at all follow-up time points (Fig 2). At
Fig 1. Kaplan-Meier estimates of cumulative annualised mortality rates between men and women
accessing ART.
https://doi.org/10.1371/journal.pone.0184124.g001
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<20 1 16.32 6.1 (0.2–34.1) 3 86.31 3.5 (0.7–10.2) 1.76 (0.18–16.92) 0.624
20–24 10 84.42 11.8 (5.7–21.8) 22 568.07 3.9 (2.4–5.9) 3.06 (1.45–6.46) 0.003
25 162 2460.88 6.6 (5.6–7.7) 213 4808.60 4.4 (3.9–5.1) 1.49 (1.21–1.83) <0.001
Baseline CD4+ count (cells/mm3)
<50 67 626.59 10.7 (8.3–13.6) 85 1039.12 8.2 (6.5–10.1) 1.31 (0.95–1.8) 0.098
50–200 85 1563.29 5.4 (4.3–6.7) 128 3343.48 3.8 (3.2–4.6) 1.42 (1.08–1.87) 0.012
>200 13 250.01 5.2 (2.8–8.9) 16 777.17 2.1 (1.2–3.3) 2.53 (1.22–5.26) 0.013
https://doi.org/10.1371/journal.pone.0184124.t002
Fig 2. Mean CD4+ cell count change from baseline over time.
https://doi.org/10.1371/journal.pone.0184124.g002
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72 months of ART, mean CD4+ cell count gain was 378.4 cells/mm3 and 556.6 cells/mm3,
p = 0.001 among men and women respectively (Fig 2). Multivariate linear mixed model
showed a significant interaction between gender and follow-up time suggesting significantly
different CD4+ cell count recovery between men and women; p = 0.001 (Fig 2).
Adjusted proportional hazards regression analysis showed that men had a 29% higher risk
of death compared to women (adjusted hazard ratio (aHR): 1.29, 95% CI: 1.05–1.58, p = 0.016
(Table 3). Risk of mortality varied by pre-ART CD4+ cell count. Compared to patients with
baseline CD4+ cell counts >200 cells/mm3, there was a 4-fold higher risk of death among
patients with a baseline CD4+ cell count<50 cells/mm3 (aHR: 3.86, 95% CI: 2.55–5.84),
p<0.0001, and a two-fold higher risk of death among patients with a baseline CD4+ cell count
between 50–200 cells/mm3, (aHR: 1.94, 95%CI: 1.30–2.91), p = 0.001, (Table 3).
In addition, patients presenting with no TB at ART initiation or a higher mean log viral
load or WHO stage 4 disease had significantly higher risk of death (Table 3).
We found that the attributable risk of death among patients initiating ART was 24.3% (95%
CI 17.3–30.5) for patients with a low baseline CD4+ cell count and 10.2% (95% CI 2.7–16.9)
for male patients (Table 4).
Of note, sensitivity analysis evaluating the impact of ART programme maturity on the effect
of gender on mortality showed that mortality rates between men and women was consistently
two-fold higher and significantly different at all follow-up time-points between 2009–2013.
This finding did not hold for the period 2004–2008 during the period of ART initiation
(Table 5).
Discussion
We provide evidence of gender disparities between HIV infected men and women in access
and response to antiretroviral therapy. Clinical outcomes differed by gender; with men dem-
onstrating higher overall mortality rates and suboptimal immunologic recovery.
Table 3. Analysis of factors associated with mortality.
Variable at ART initiation Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Gender (ref: women) Male 1.41 (1.16–1.72) 0.001 1.29 (1.05–1.58) 0.016
Age (per 5 year increase) 1.03 (0.97–1.08) 0.364 1.04 (0.98–1.10) 0.182
Site (ref: rural) Urban 0.82 (0.67–1.01) 0.061 0.90 (0.70–1.16) 0.410
Baseline CD4+ cell count (ref:>200), cells/mm3 <50 4.10 (2.75–6.10) <.0001 3.86 (2.55–5.84) <.0001
50–200 1.89 (1.28–2.79) 0.001 1.94 (1.30–2.91) 0.001
Viral load (log10 copies/ml) 1.52 (1.31–1.76) <0.001 1.30 (1.11–1.52) 0.001
Tuberculosis (ref: Yes) No 1.26 (0.98–1.61) 0.0711 1.74 (1.33–2.28) <.0001
WHO stage (ref: 1–3) Stage 4 2.49 (1.97–3.15) <.0001 2.32 (1.80–2.99) <.0001
Past history of TB (ref: No) Yes 1.20 (0.97–1.47) 0.092 1.04 (0.81–1.33) 0.759
https://doi.org/10.1371/journal.pone.0184124.t003
Table 4. Impact of different risk factors on mortality.
Variable Attributable risk (95% CI)
Male 10.2% (2.7–16.9)
CD4+ cell count <50cells/mm3 24.3% (17.3–30.5)
WHO stage 4 13.2% (9.0–18.1)
No TB prevalence 24.2% (7.0–40.8)
https://doi.org/10.1371/journal.pone.0184124.t004
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Mortality
The bulk of deaths in both men and women occurred in the first 24 months of follow-up con-
curring with findings from other studies [18,19]. Despite ART access, all patients showed
unacceptably high mortality rates with men having 50% higher mortality rate compared
women throughout follow-up and their mortality was consistently higher irrespective of base-
line CD4+ cell counts. Results from sensitivity analyses, which assumed that all patients who
were lost to follow-up died, and that all patients who were lost to follow-up within six months
of ART initiation died, were consistent with the main findings (S1 Table).
After removing the confounding effect of age, mortality rates observed in men and women
in our study was lower than the age-standardised mortality rates. Interestingly, mortality rates
among men and women in the study population closely approximated age-standardised mor-
tality when we assumed that patients who were loss to follow-up within 6 months of ART initi-
ation died.
In contrast to the epidemiological data of the evolving epidemic in southern Africa wherein
HIV acquisition does not occur in men until their late twenties [20,21] and we found that the
highest mortality rates were in young men between the ages of 20–24 years. However, we had
a very small number of men less than 24 years of age enrolled into the programme.
Conversely, studies from developed countries show differing results, finding no gender dif-
ferences in clinical, virological and immunological outcomes among HIV infected men and
women initiating ART [22,23]. A multi-site cohort study found higher rates of virological
rebound in women [7]. Studies conducted elsewhere in SSA also demonstrate poor outcomes
among men on ART with respect to higher rates of mortality and loss-to-follow-up [24,25].
Published literature from South Africa support our findings and demonstrates that while life
expectancy was not significantly different pre-ART between genders; in 2011 women were
27% less likely to die from HIV than men [26].
Risk factors for poor clinical outcomes
Poor prognostic markers of ART response were apparent in men at baseline, who were older,
had lower CD4+ cell counts and higher viral loads compared to women. This finding concurs
with published South African literature demonstrating that compared to men, women were
more likely to access HIV testing, and among those testing HIV positive, women were younger
with higher CD4+ cell counts than their male counterparts [27].
This study also showed that the late presentation of men was associated with poor immuno-
logical response to ART with higher risk of morbidity and mortality [27]. Our findings of
significant correlation between baseline characteristics, virological suppression rates, immuno-
logic recovery and mortality concur with previously published studies conducted in South
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† Assumes all patients who were loss to follow-up died
‡ Assumes all patients who were loss to follow-up within 6 months of ART initiation died
https://doi.org/10.1371/journal.pone.0184124.t005
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Africa [28,29]. There were no significant differences in virologic suppression in follow-up
between men and women. Notwithstanding the greater than 90% virologic suppression rate
on ART, men remained at higher risk of dying, emphasising the impact of advanced HIV dis-
ease at baseline on subsequent antiretroviral treatment response. We found significantly differ-
ent CD4+ cell count recovery between men and women with men consistently demonstrated
significantly smaller CD4+ cell count increases compared to women during longitudinal fol-
low-up. Given that viral load suppression was similar between sexes, women however had
higher CD4+ cell counts indicating that there may be underlying genetic differences in ART
response.
We show that during follow up overall mortality rate halved among men and women with
baseline CD4+ cell counts of 50–200 cells/mm3 in comparison with those patients that pre-
sented with baseline CD4+ cell counts of less than 50 cells/mm3. Furthermore, we found that
the mortality risk among patients initiating ART was attributable to both low baseline CD4+
cell count and male gender, corroborating published literature showing that baseline CD4+
cell count is an important factor impacting CD4+ cell count increase and recovery on treat-
ment [30]. In settings that are still guided by CD4+ cell count thresholds for ART initiation
consideration should be given for men to access ART at higher CD4+ cell counts.
Our findings demonstrate that the absence of a diagnosis of prevalent TB increased risk of
mortality. Published literature has cited that undiagnosed TB is higher among patients access-
ing ART than in the general population; with the majority of incident TB diagnosed in the
early weeks of ART initiation being TB prevalent but missed at baseline screening [19,31,32].
It is possible that undiagnosed TB at ART initiation also contributed to higher risk of mortality
in our study. The magnitude of the TB epidemic, burden of disease and varied presentation of
TB in HIV infected individuals may have contributed to missed TB diagnosis.
Programmatic outcomes
Men had higher lost to follow-up rates in our cohort in keeping with reports from published
literature [33,34]. Adverse clinical outcomes notably death can be masked by LTFU resulting
in the underestimation of actual mortality rates within ART programmes [35]. Previous South
African studies have documented gender differences in service uptake within the HIV care cas-
cade; women have higher rates of HIV testing [27] and linkage to care than men [13]. Once
initiated on ART, men have poorer adherence [36] and lower retention in care [28,35]. Govin-
dasamy et al in a systematic review of 42 publications from 12 countries showed high attrition
of men from pre-ART and ART programmes [37]. These studies did not however describe
mortality differentials between the genders. Overall, the design and results of this article are
similar to those found by Cornell et al [28].
Limitations
As this was a secondary analysis of routinely collected programme data, missing data limited
our ability to comment on various correlations e.g. the impact of socio-economic and demo-
graphic variables on clinical outcomes. Treatment adherence was not measured and its impact
on outcomes could be underestimated. We have not investigated other biological and beha-
vioural factors that may have contributed to poor ART outcomes in men. While the vast
majority of patients enrolled into this cohort were women, we had very few pregnancies and
are therefore unable to comment on the impact of pregnancy in women on mortality in this
cohort. Additional studies that explore potential barriers that South African men experience
when seeking HIV care, and optimal strategies to link and engage men in ART services, is
warranted.
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Conclusion
While heterosexual transmission is the primary mode of HIV transmission in sub Saharan
Africa, the impact of free ART provision on access and clinical outcomes in men and women
is unequal. Men presented late for ART initiation with more advanced disease and a higher
mortality rate compared to women in this six-year ART program. The increased feminization
of the HIV epidemic in sub Saharan Africa has rightfully demanded that greater focus be given
to women with respect to HIV prevention, transmission, treatment and care. However, in a
predominantly heterosexual epidemic, greater programmatic effort should be directed toward
encouraging men to test early and frequently. As we prepare to scale-up “Test and Treat” in all
HIV infected patients, innovative strategies are needed to ensure that men and women that
test HIV positive have access to effective linkage to care for early ART initiation to achieve the
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